Account
Insider Insights
03.03.2022
NICE recommends routine use of Zejula

The National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...

Read more
Insider Insights
28.02.2022
UK first rare disease action plan

On 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...

Read more
News
23.02.2022
PMA Insights: Week 8

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
15.02.2022
NICE recommends CDF use of dostarlimab

The CDF allows patients to access a new treatment while further data is collected on its clinical an...

Read more
Insider Insights
10.02.2022
Institute of Cancer Research labels NICE

In a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...

Read more
Insider Insights
07.02.2022
NHS England announces access deal for Libmeldy

The news comes after the health service negotiated a “significant confidential discount” to the ...

Read more
Articles
02.02.2022
Developing a STA/HST submission to NICE

NICE require a broad range of evidence to be included within the reimbursement dossier, including cl...

Read more
Insider Insights
01.02.2022
UK NICE recommends selective laser therapy

According to updated guidelines published by NICE, patients newly diagnosed with glaucoma and ocular...

Read more
Articles
01.02.2022
Changes to NICE's health technology evaluation

This reforms have been welcomed by the industry as they should support faster access to medicines as...

Read more
Insider Insights
01.02.2022
NICE changes to its methods and processes

The changes cover how topics are chosen, the steps and stages in each evaluation and how evidence is...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.